Bismuth Subsalicylate

Curling Ulcer, Indigestion, Flatulence + 9 more
Treatment
16 FDA approvals
20 Active Studies for Bismuth Subsalicylate

What is Bismuth Subsalicylate

Bismuth subsalicylateThe Generic name of this drug
Treatment SummaryBismuth subsalicylate is a medication used to relieve nausea, diarrhea, and stomach discomfort. It is an antacid and anti-diarrheal agent that has been around for over 100 years and was approved by the FDA in 1939. It is an active ingredient in Pepto-Bismol, an over-the-counter medication, and is also a key component of HELIDAC Therapy, a treatment regimen used to treat patients with an infection of the bacteria H. pylori.
Topcare stomach relief original strengthis the brand name
image of different drug pills on a surface
Bismuth Subsalicylate Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Topcare stomach relief original strength
Bismuth subsalicylate
1989
4

Approved as Treatment by the FDA

Bismuth subsalicylate, also called Topcare stomach relief original strength, is approved by the FDA for 16 uses such as Indigestion and Helicobacter Pylori Infection .
Indigestion
Helicobacter Pylori Infection
Used to treat Helicobacter Pylori Infection in combination with Metronidazole
Gastroenteritis
Traveler's Diarrhea
Curling Ulcer
Used to treat Duodenal Ulcer in combination with Metronidazole
Heartburn
Used to treat Heartburn in combination with Calcium carbonate
Upset stomach
Flatulence
Duodenal Ulcer
Used to treat Duodenal Ulcer in combination with Metronidazole
Heartburn
Used to treat Heartburn in combination with Calcium carbonate
Diarrhea
belching
Flatulence
gastrointestinal fullness
Diarrhea
Gastrointestinal distress

Effectiveness

How Bismuth Subsalicylate Affects PatientsBismuth subsalicylate is a drug with multiple benefits, such as reducing flatulence and diarrhea, relieving gastrointestinal discomfort, and preventing traveler's diarrhea. It also has antimicrobial properties, which can help to fight certain bacteria, including the bacteria that causes stomach ulcers (_Helicobacter pylori_) and other enteric pathogens like _Clostridium difficile_ and _Salmonella_. Bismuth subsalicylate can be used together with other drugs to help treat stomach ulcers.
How Bismuth Subsalicylate works in the bodyBismuth subsalicylate works by breaking down into two substances, salicylic acid and bismuth, in the stomach. The bismuth then binds to other molecules in the stomach to create bismuth salts, which have antimicrobial properties that stop bacteria from sticking to and growing on the stomach's mucosal cells. The salicylic acid acts as an anti-inflammatory, preventing the formation of pro-inflammatory molecules. Bismuth subsalicylate also helps protect the stomach from further damage, and prevents bacteria from performing certain activities like making enzymes. Altogether, these properties help heal ulcers in

When to interrupt dosage

The quantity of Bismuth Subsalicylate is reliant upon the identified disorder, like Nausea, Flatulence and Diarrhea. The amount of dosage is contingent upon the technique of delivery indicated in the table beneath.
Condition
Dosage
Administration
Gastrointestinal distress
, 52.5 mg/mL, 26.2 mg/mL, 105.0 mg/mL, 262.0 mg, 17.47 mg/mL, 35.0 mg/mL, 2.62 mg/mg, 525.0 mg, 17.5 mg/mL, 300.0 mg, 1.7 %, 524.0 mg, 52.5 mg, 262.4 mg, 17.66 mg/mL, 17.6 mg/mL, 35.2 mg/mL, 23.6 mg/mL, 0.262 mg/mg
Oral, Suspension, Suspension - Oral, , Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, Powder - Oral, Kit, Tablet, film coated - Oral, Tablet, film coated, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Syrup, Syrup - Oral, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated
Gastroenteritis
, 52.5 mg/mL, 26.2 mg/mL, 105.0 mg/mL, 262.0 mg, 17.47 mg/mL, 35.0 mg/mL, 2.62 mg/mg, 525.0 mg, 17.5 mg/mL, 300.0 mg, 1.7 %, 524.0 mg, 52.5 mg, 262.4 mg, 17.66 mg/mL, 17.6 mg/mL, 35.2 mg/mL, 23.6 mg/mL, 0.262 mg/mg
Oral, Suspension, Suspension - Oral, , Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, Powder - Oral, Kit, Tablet, film coated - Oral, Tablet, film coated, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Syrup, Syrup - Oral, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated
Diarrhea
, 52.5 mg/mL, 26.2 mg/mL, 105.0 mg/mL, 262.0 mg, 17.47 mg/mL, 35.0 mg/mL, 2.62 mg/mg, 525.0 mg, 17.5 mg/mL, 300.0 mg, 1.7 %, 524.0 mg, 52.5 mg, 262.4 mg, 17.66 mg/mL, 17.6 mg/mL, 35.2 mg/mL, 23.6 mg/mL, 0.262 mg/mg
Oral, Suspension, Suspension - Oral, , Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, Powder - Oral, Kit, Tablet, film coated - Oral, Tablet, film coated, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Syrup, Syrup - Oral, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated
Diarrhea
, 52.5 mg/mL, 26.2 mg/mL, 105.0 mg/mL, 262.0 mg, 17.47 mg/mL, 35.0 mg/mL, 2.62 mg/mg, 525.0 mg, 17.5 mg/mL, 300.0 mg, 1.7 %, 524.0 mg, 52.5 mg, 262.4 mg, 17.66 mg/mL, 17.6 mg/mL, 35.2 mg/mL, 23.6 mg/mL, 0.262 mg/mg
Oral, Suspension, Suspension - Oral, , Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, Powder - Oral, Kit, Tablet, film coated - Oral, Tablet, film coated, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Syrup, Syrup - Oral, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated
gastrointestinal fullness
, 52.5 mg/mL, 26.2 mg/mL, 105.0 mg/mL, 262.0 mg, 17.47 mg/mL, 35.0 mg/mL, 2.62 mg/mg, 525.0 mg, 17.5 mg/mL, 300.0 mg, 1.7 %, 524.0 mg, 52.5 mg, 262.4 mg, 17.66 mg/mL, 17.6 mg/mL, 35.2 mg/mL, 23.6 mg/mL, 0.262 mg/mg
Oral, Suspension, Suspension - Oral, , Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, Powder - Oral, Kit, Tablet, film coated - Oral, Tablet, film coated, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Syrup, Syrup - Oral, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated
belching
, 52.5 mg/mL, 26.2 mg/mL, 105.0 mg/mL, 262.0 mg, 17.47 mg/mL, 35.0 mg/mL, 2.62 mg/mg, 525.0 mg, 17.5 mg/mL, 300.0 mg, 1.7 %, 524.0 mg, 52.5 mg, 262.4 mg, 17.66 mg/mL, 17.6 mg/mL, 35.2 mg/mL, 23.6 mg/mL, 0.262 mg/mg
Oral, Suspension, Suspension - Oral, , Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, Powder - Oral, Kit, Tablet, film coated - Oral, Tablet, film coated, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Syrup, Syrup - Oral, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated
Curling Ulcer
, 52.5 mg/mL, 26.2 mg/mL, 105.0 mg/mL, 262.0 mg, 17.47 mg/mL, 35.0 mg/mL, 2.62 mg/mg, 525.0 mg, 17.5 mg/mL, 300.0 mg, 1.7 %, 524.0 mg, 52.5 mg, 262.4 mg, 17.66 mg/mL, 17.6 mg/mL, 35.2 mg/mL, 23.6 mg/mL, 0.262 mg/mg
Oral, Suspension, Suspension - Oral, , Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, Powder - Oral, Kit, Tablet, film coated - Oral, Tablet, film coated, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Syrup, Syrup - Oral, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated
Indigestion
, 52.5 mg/mL, 26.2 mg/mL, 105.0 mg/mL, 262.0 mg, 17.47 mg/mL, 35.0 mg/mL, 2.62 mg/mg, 525.0 mg, 17.5 mg/mL, 300.0 mg, 1.7 %, 524.0 mg, 52.5 mg, 262.4 mg, 17.66 mg/mL, 17.6 mg/mL, 35.2 mg/mL, 23.6 mg/mL, 0.262 mg/mg
Oral, Suspension, Suspension - Oral, , Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, Powder - Oral, Kit, Tablet, film coated - Oral, Tablet, film coated, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Syrup, Syrup - Oral, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated
Upset stomach
, 52.5 mg/mL, 26.2 mg/mL, 105.0 mg/mL, 262.0 mg, 17.47 mg/mL, 35.0 mg/mL, 2.62 mg/mg, 525.0 mg, 17.5 mg/mL, 300.0 mg, 1.7 %, 524.0 mg, 52.5 mg, 262.4 mg, 17.66 mg/mL, 17.6 mg/mL, 35.2 mg/mL, 23.6 mg/mL, 0.262 mg/mg
Oral, Suspension, Suspension - Oral, , Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, Powder - Oral, Kit, Tablet, film coated - Oral, Tablet, film coated, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Syrup, Syrup - Oral, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated
Flatulence
, 52.5 mg/mL, 26.2 mg/mL, 105.0 mg/mL, 262.0 mg, 17.47 mg/mL, 35.0 mg/mL, 2.62 mg/mg, 525.0 mg, 17.5 mg/mL, 300.0 mg, 1.7 %, 524.0 mg, 52.5 mg, 262.4 mg, 17.66 mg/mL, 17.6 mg/mL, 35.2 mg/mL, 23.6 mg/mL, 0.262 mg/mg
Oral, Suspension, Suspension - Oral, , Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, Powder - Oral, Kit, Tablet, film coated - Oral, Tablet, film coated, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Syrup, Syrup - Oral, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated
Helicobacter Pylori Infection
, 52.5 mg/mL, 26.2 mg/mL, 105.0 mg/mL, 262.0 mg, 17.47 mg/mL, 35.0 mg/mL, 2.62 mg/mg, 525.0 mg, 17.5 mg/mL, 300.0 mg, 1.7 %, 524.0 mg, 52.5 mg, 262.4 mg, 17.66 mg/mL, 17.6 mg/mL, 35.2 mg/mL, 23.6 mg/mL, 0.262 mg/mg
Oral, Suspension, Suspension - Oral, , Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, Powder - Oral, Kit, Tablet, film coated - Oral, Tablet, film coated, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Syrup, Syrup - Oral, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated
Heartburn
, 52.5 mg/mL, 26.2 mg/mL, 105.0 mg/mL, 262.0 mg, 17.47 mg/mL, 35.0 mg/mL, 2.62 mg/mg, 525.0 mg, 17.5 mg/mL, 300.0 mg, 1.7 %, 524.0 mg, 52.5 mg, 262.4 mg, 17.66 mg/mL, 17.6 mg/mL, 35.2 mg/mL, 23.6 mg/mL, 0.262 mg/mg
Oral, Suspension, Suspension - Oral, , Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, Powder - Oral, Kit, Tablet, film coated - Oral, Tablet, film coated, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Syrup, Syrup - Oral, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated

Warnings

Bismuth Subsalicylate Contraindications
Condition
Risk Level
Notes
Stomach Ulcer
Do Not Combine
Blood in Stool
Do Not Combine
Pulse Frequency
Do Not Combine
Melena
Do Not Combine
Fever
Do Not Combine
Gastrointestinal Hemorrhage
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Bismuth Subsalicylate may interact with Pulse Frequency
There are 20 known major drug interactions with Bismuth Subsalicylate.
Common Bismuth Subsalicylate Drug Interactions
Drug Name
Risk Level
Description
Bismuth subcarbonate
Major
Bismuth subsalicylate may increase the neurotoxic activities of Bismuth subcarbonate.
Bismuth subcitrate potassium
Major
Bismuth subsalicylate may increase the neurotoxic activities of Bismuth subcitrate potassium.
Bismuth subgallate
Major
Bismuth subsalicylate may increase the neurotoxic activities of Bismuth subgallate.
Bismuth subnitrate
Major
Bismuth subsalicylate may increase the neurotoxic activities of Bismuth subnitrate.
Probenecid
Major
The therapeutic efficacy of Probenecid can be decreased when used in combination with Bismuth subsalicylate.
Bismuth Subsalicylate Toxicity & Overdose RiskThe lowest toxic dose of bismuth subsalicylate in humans is 700mg/kg. In rats, the toxic dose is 1200mg/kg when taken orally, 542mg/kg when given via intraperitoneal route, and 980mg/kg when given subcutaneously. Taking too much bismuth subsalicylate over a long period of time can cause blackened tongue and teeth, fatigue, changes in mood, mental deterioration, and nerve damage. Other symptoms can include difficulty thinking, shaking, feeling tired, difficulty sleeping, confusion, twitching, seizures, depression, anxiety, and low mood
image of a doctor in a lab doing drug, clinical research

Bismuth Subsalicylate Novel Uses: Which Conditions Have a Clinical Trial Featuring Bismuth Subsalicylate?

68 active research projects are investigating the potential of Bismuth Subsalicylate to regulate Flatulence, Gastrointestinal Fullness and Curling Ulcer.
Condition
Clinical Trials
Trial Phases
Gastroenteritis
12 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Early Phase 1
Curling Ulcer
0 Actively Recruiting
Diarrhea
0 Actively Recruiting
Diarrhea
0 Actively Recruiting
gastrointestinal fullness
0 Actively Recruiting
Indigestion
6 Actively Recruiting
Phase 3, Not Applicable, Phase 2
Helicobacter Pylori Infection
2 Actively Recruiting
Not Applicable, Phase 4
Flatulence
0 Actively Recruiting
Heartburn
2 Actively Recruiting
Phase 3, Not Applicable
Upset stomach
0 Actively Recruiting
belching
0 Actively Recruiting
Gastrointestinal distress
9 Actively Recruiting
Phase 2, Early Phase 1, Phase 1, Phase 3, Not Applicable, Phase 4

Bismuth Subsalicylate Reviews: What are patients saying about Bismuth Subsalicylate?

5Patient Review
5/25/2012
Bismuth Subsalicylate for Indigestion
I had gastric bypass surgery six years ago and I still have trouble digesting my food. This medication has helped me be able to eat, but now my tongue is black. I'm not comfortable with this because it's not a temporary side effect; I have to take the medication every time I eat. I don't want to walk around with a black tongue for the rest of my life.
5Patient Review
10/14/2013
Bismuth Subsalicylate for Diarrhea
After trying reglan and diociline without success, I decided to just take this medication myself. The results were almost instantaneous and very impressive.
5Patient Review
4/18/2009
Bismuth Subsalicylate for Diarrhea
4.7Patient Review
5/11/2016
Bismuth Subsalicylate for Diarrhea
My doctor recommended this for my colitis-related diarrhea, and it's been working great! I take it three times a day when I'm having issues, and it's really helped. Of course, I still have to be careful about what I eat, but this has made a big difference.
2.7Patient Review
9/8/2010
Bismuth Subsalicylate for Indigestion
Pepto-Bismol has been a game changer for me. I take two pills in the morning and two in the evening, as per my doctor's orders, and I haven't felt this good in over 20 years.
2Patient Review
10/29/2014
Bismuth Subsalicylate for Diarrhea
Unfortunately, my condition worsened after taking this treatment.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about bismuth subsalicylate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who should not take bismuth subsalicylate?

"This product is not recommended for children or teens under the age of 18 who have chickenpox, the flu, or any undiagnosed illness, or who have recently received a vaccine. Taking aspirin or aspirin-like products in these cases increases the risk of developing Reye's syndrome, a rare but serious illness."

Answered by AI

Is bismuth subsalicylate the same as Pepto-Bismol?

"The brand name for bismuth subsalicylate is Pepto-Bismol. Bismuth has antimicrobial effects against certain bacteria that cause diarrhea, while subsalicylate has antisecretory effects against fluid and electrolyte loss. Bismuth subsalicylate also has anti-inflammatory actions on the stomach and intestinal lining."

Answered by AI

When should you take bismuth subsalicylate?

"For diarrhea or upset stomach:

Adults and teenagers should take 2 tablets every half hour to one hour. You should not take more than 16 tablets in twenty-four hours. Children should not use this medication."

Answered by AI

Does bismuth subsalicylate have side effects?

"Side effects of bismuth subsalicylate can include changes in behaviour, nausea and vomiting, hearing loss or ringing in the ears, diarrhoea lasting longer than 2 days, or worsening of stomach symptoms."

Answered by AI

Clinical Trials for Bismuth Subsalicylate

Have you considered Bismuth Subsalicylate clinical trials? We made a collection of clinical trials featuring Bismuth Subsalicylate, we think they might fit your search criteria.Go to Trials
Image of Montefiore Medical Center in Bronx, United States.

Fosaprepitant vs Metoclopramide for Nausea and Vomiting

18+
All Sexes
Bronx, NY
The study team proposes a double-blind, comparative effectiveness, randomized controlled trial (RCT) to address the following goal: to determine the relative efficacy and adverse event profile of fosaprepitant compared to the standard of care antiemetic metoclopramide. Fosaprepitant and its active metabolite aprepitant are a relatively new class of antiemetic that exclusively acts in the central nervous system by blocking neurokinin (NK-1) which is a key signaling molecule in the centrally mediated aspects of the vomiting reflex. Currently, fosaprepitant and aprepitant both have only two United Stated Food and Drug Administration (USFDA) approved indications for nausea and vomiting: chemotherapy-induced and postoperative. Neurokinin inhibitors are highly effective and generally well-tolerated. Therefore, this class of medication may be a more appropriate medication for the millions of patients with nausea and vomiting that seek care in emergency departments (EDs). Intravenous fosaprepitant is converted to the active metabolite aprepitant on the order of minutes and is significantly cheaper to procure at this time.
Phase 4
Waitlist Available
Montefiore Medical Center (+1 Sites)Benjamin Friedman, MD
Image of Brigham and Women's Hospital in Boston, United States.

Low Thermal Plasma for Marginal Ulcers

18+
All Sexes
Boston, MA
The objective of the study is to investigate the treatment of marginal ulcers with Low Thermal plasma in an endoscopic setting. By a treatment of the ulcerated areas with argon plasma with low power settings (\~ 1 W) we hypothesize that the size of the ulcers will shrink, and the healing is accelerated compared to standard of care alone. Patients will benefit from this minimally invasive approach compared to a much more invasive surgical approach that comes with higher risks and hospital stay length time. From a societal and scientific perspective, this study aims to extend the well-documented clinical benefits of plasma technology - from external wound healing to internal ulcer treatment - within an endoscopic framework. The success of this study could pave the way for broader applications of LTP in the treatment of other endoscopically accessible conditions such as peptic ulcers, duodenal ulcers and esophageal ulcers. This advancement has the potential not only to improve patient outcomes through less invasive methods, but also to position LTP as a cornerstone in the future of gastroenterological wound management strategies.
Recruiting
Has No Placebo
Brigham and Women's HospitalChristopher C. Thompson, MD, MSc
Have you considered Bismuth Subsalicylate clinical trials? We made a collection of clinical trials featuring Bismuth Subsalicylate, we think they might fit your search criteria.Go to Trials
Image of Montefiore Medical Center (Montefiore and Weiler EDs) in Bronx, United States.

Fosaprepitant for Nausea and Vomiting

18+
All Sexes
Bronx, NY
The study team proposes a randomized, double-blind, RCT to address the following goal: to determine the relative efficacy and adverse event profile of fosaprepitant compared to the standard of care antiemetic ondansetron. Fosaprepitant and its active metabolite aprepitant are a relatively new class of antiemetic that exclusively acts in the central nervous system by blocking neurokinin (NK-1) which is a key signaling molecule in the centrally mediated aspects of the vomiting reflex. Currently, fosaprepitant and aprepitant both have only two United Stated Food and Drug Administration (USFDA) approved indications for nausea and vomiting: chemotherapy-induced and postoperative. Neurokinin inhibitors are highly effective and generally well-tolerated. Therefore, this class of medication may be a more appropriate medication for the millions of patients with nausea and vomiting that seek care in EDs. Intravenous fosaprepitant is converted to the active metabolite aprepitant on the order of minutes and is significantly cheaper to procure at this time. The outcome for the efficacy analysis will be no need for additional medication to treat nausea and vomiting within 2 hours of investigational medication administration. The primary outcome for the tolerability analysis will be the development of any new symptom within 2 hours of medication administration.
Phase 2 & 3
Recruiting
Montefiore Medical Center (Montefiore and Weiler EDs) (+1 Sites)Benjamin W Friedman, MD MS
Image of G. Oppenheimer Center for Neurobiology of Stress and Resilience in Los Angeles, United States.

Biofeedback for Functional Abdominal Bloating

18 - 80
All Sexes
Los Angeles, CA
Background. Abdominal distention is produced by an abnormal somatic postural tone. The authors developed an original biofeedback technique. In a randomized, placebo-controlled trial the authors demonstrated the superiority of biofeedback over placebo for the treatment of abdominal distention. However, the technique is technically complex and unpractical. Aim. To prove the efficacy of a noninstrumental biofeedback technique, transmitted by a standard training program, for the treatment of abdominal distension in different centers. Selection criteria. Episodes of visible abdominal distension. Intervention. Patients will be randomized into biofeedback and placebo groups. Three sessions of either biofeedback or placebo intervention will be performed during the first 3 weeks of the intervention period. Biofeedback: Patients will be taught to control abdominal and thoracic muscular activity by providing instructions using an original video support. In each center one operator will receive a standard training on how to deliver the noninstrumental biofeedback treatment. Patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period. Placebo: Sham measurements of abdominal and thoracic motion will be performed, and a pill of placebo containing 0.21 g glucose will be administered; patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
Recruiting
Paid Trial
G. Oppenheimer Center for Neurobiology of Stress and Resilience (+1 Sites)Fernando Azpiroz, MD
Have you considered Bismuth Subsalicylate clinical trials? We made a collection of clinical trials featuring Bismuth Subsalicylate, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security